ImexpharmSTC:IMP -1.98%98 EV-to-FCF is 22.36 as of Jun. 27, 2026, which is 110% above its 10-year median of 10.64. GuruFocus rates STC:IMP with a GF Score™ of 98/100 and a GF Value™ of ₫51,706.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 562 Drug Manufacturers companies, Imexpharm ranks worse than 54.98% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Imexpharm's Enterprise Value is ₫6,214,227 Mil.
Imexpharm's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₫277,856 Mil. Therefore, Imexpharm's EV-to-FCF for today is 22.36.
The historical rank and industry rank for Imexpharm's EV-to-FCF or its related term are showing as below:
STC:IMP'
s EV-to-FCF Range Over the Past 10 Years
Min: -5639.95 Med: 10.64 Max: 582.56
Current: 24.28
During the past 13 years, the highest EV-to-FCF of Imexpharm was 582.56. The lowest was -5639.95. And the median was 10.64.
STC:IMP's EV-to-FCF is ranked worse than 54.98% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.11
vs STC:IMP: 24.28
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Imexpharm's share price for today is ₫42050.00.
Imexpharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₫903.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Imexpharm EV-to-FCF Related Terms
Imexpharm EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Imexpharm's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imexpharm EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Imexpharm's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Imexpharm's EV-to-FCF falls into.
Imexpharm's current Enterprise Value is ₫6,214,227 Mil.
Imexpharm's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₫277,856 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imexpharm (STC:IMP) has a EV-to-FCF of 22.36 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Imexpharm and its competitors. This is 110% above median its historical median of 10.64. According to the industry distribution chart, Imexpharm ranks #309 out of 562 companies in the Drug Manufacturers industry, placing it in the top 55%.
Is Imexpharm's EV-to-FCF too high?
Imexpharm's current EV-to-FCF of 22.36 is 110% above median its 10-year median of 10.64. The Drug Manufacturers industry median EV-to-FCF is 20.11. Imexpharm's value of 22.36 is 11.2% above this industry median. Based on the distribution chart, Imexpharm ranks #309 out of 562 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Imexpharm has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Imexpharm ranks #309 out of 562 companies for EV-to-FCF. This places Imexpharm in the lower half of its industry. The industry median EV-to-FCF is 20.11. Imexpharm's value of 22.36 is 11.2% above this benchmark. While the company's 10-year median is 10.64 vs. the industry median of 20.11, Imexpharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.11, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imexpharm's current EV-to-FCF of 22.36 is 11.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Imexpharm and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imexpharm's current EV-to-FCF is 22.36, which is 110% above median its own 10-year median of 10.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫51,706.57, compared to a current price of ₫42,050.00 — trading 18.7% below its estimated fair value. The current EV-to-FCF is 22.36, which is 110% above median its 10-year median of 10.64 and 11.2% above the Drug Manufacturers industry median of 20.11. Imexpharm's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current EV-to-FCF is 22.36 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imexpharm (STC:IMP) Overvalued in 2026?
Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued.
The current stock price of ₫42,050.00 is trading 18.7% below its estimated GF Value™ of ₫51,706.57.
GuruFocus considers Imexpharm to be Modestly Undervalued.
Key valuation signals for STC:IMP:
EV-to-FCF: 22.36 (110% above median its 10-year median of 10.64)
GF Value™: ₫51,706.57 vs. price of ₫42,050.00 (18.7% below fair value)
Industry Position: 11.2% above the Drug Manufacturers median (#309 of 562)
No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score
Get the complete analysis for STC:IMP
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:IMP has been successfully added to your 
